InVitae Corp (NYSE:NVTA) insider Katherine Stueland sold 3,789 shares of InVitae stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $22.49, for a total value of $85,214.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Katherine Stueland also recently made the following trade(s):
- On Thursday, June 13th, Katherine Stueland sold 3,789 shares of InVitae stock. The shares were sold at an average price of $19.36, for a total value of $73,355.04.
- On Wednesday, May 15th, Katherine Stueland sold 1,000 shares of InVitae stock. The shares were sold at an average price of $18.36, for a total value of $18,360.00.
Shares of InVitae stock opened at $24.78 on Friday. The firm has a market cap of $2.11 billion, a price-to-earnings ratio of -12.77 and a beta of 2.52. InVitae Corp has a 52-week low of $7.73 and a 52-week high of $26.77. The company has a 50 day moving average price of $21.16. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.73 and a current ratio of 7.73.
InVitae (NYSE:NVTA) last posted its quarterly earnings results on Tuesday, May 7th. The medical research company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.01). The company had revenue of $40.55 million for the quarter, compared to analyst estimates of $47.17 million. InVitae had a negative return on equity of 65.76% and a negative net margin of 81.52%. The firm’s revenue for the quarter was up 46.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.66) EPS. As a group, analysts anticipate that InVitae Corp will post -1.88 EPS for the current fiscal year.
A number of brokerages recently issued reports on NVTA. Chardan Capital reissued a “buy” rating and issued a $30.00 target price on shares of InVitae in a research report on Tuesday, June 11th. Oppenheimer began coverage on Focus Financial Partners in a research report on Monday, April 8th. They issued an “outperform” rating and a $48.00 target price on the stock. Benchmark lifted their target price on InVitae from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, July 12th. Finally, Zacks Investment Research lowered Heritage Insurance from a “hold” rating to a “strong sell” rating in a research report on Friday, April 26th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. InVitae presently has an average rating of “Buy” and a consensus price target of $26.40.
Several large investors have recently bought and sold shares of NVTA. PNC Financial Services Group Inc. bought a new stake in InVitae in the 1st quarter valued at $26,000. Certified Advisory Corp bought a new stake in InVitae in the 1st quarter valued at $30,000. Signaturefd LLC bought a new stake in InVitae in the 1st quarter valued at $47,000. SG Americas Securities LLC bought a new stake in InVitae in the 1st quarter valued at $125,000. Finally, NumerixS Investment Technologies Inc bought a new stake in InVitae in the 4th quarter valued at $58,000. 78.93% of the stock is currently owned by hedge funds and other institutional investors.
InVitae Company Profile
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.